Brainsymphonics was established in Wisconsin in 2009 with the founders own investment. The mission of Brainsymphonics is to commercialize new imaging technologies for early detection and diagnosis of Alzheimer’s Disease (AD), enable timely and cost-effective intervention. We focus on a new neuroimaging approach that uses resting-state functional connectivity MRI (fcMRI) methods to mark network dysfunction in AD.
The company has obtained exclusive licenses of patents developed by Dr. Shi-Jiang Li’s laboratory at Medical College of Wisconsin. This project was funded by SBIR and the founders’ investment. With the current SBIR Phase II, we are in process of filing FDA De Novo Submission in 2018.
A New Neuroimaging Approach
During the last 10 years, Dr. Li’s research lab at Medical College of Wisconsin, pioneered a new neuroimaging approach that used resting-state functional connectivity MRI (fcMRI) methods to mark network dysfunction in AD. His lab demonstrated that memories loss in AD patients can be detected and characterized by changes in functional connectivity.
Our EBPS-AD is a software application that can assess the stage of Alzheimer’s Disease in individuals. The EBP Stage can help a trained physician to assess whether the subject is Cognitively Normal, Mild Cognitive Impairment, or Alzheimer’s Disease. The report is saved in PDF file format and/or stored in an electronic medical record.
Hui Hu, PhD.
Chief Executive Officer (CEO) of BrainSymphonics
Shi-Jiang Li, Ph.D.
Chief Technology Officer of BrainSymphonics and
Principal Investigator (PI) of the Subcontract at the Medical College of Wisconsin
Mike Hartmann, M.S., M.B.A.
Business Consultant of BrainSymphonics
Chief Operating Officer (COO) of BrainSymphonics
16600 W National Avenue
New Berlin, WI 53151